University of Chicago Medicine Comprehensive Cancer Center researchers have found a new treatment for advanced prostate cancer. They achieved complete tumor control and extended survival in a mouse model of prostate cancer using a three-drug regimen that targets PI3K, MEK, and Wnt/β-catenin signaling pathways. The intermittent dosing doesn’t cause long-term side effects, and a success rate of 100% was observed in the model.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
